Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature

IntroductionDrug absorption is often altered and typically diminished in patients with short bowel syndrome (SBS). It is important to understand the patient's gastrointestinal anatomy, the absorptive capacity of the remaining bowel, and the physicochemical and pharmacokinetic properties of the drug to optimize oral pharmacotherapy.Areas coveredThe primary focus was to provide an updated understanding of the absorption of various drugs in patients with short bowel syndrome. Forty-seven studies covering 13 different drug classes were included in the review and study details, patient characteristics, drug characteristics and pharmacokinetic findings were summarized for each drug class.Expert opinionImproving and simplifying drug treatment in patients with SBS have high priority, but the patients are multi diseased so knowledge regarding absorption of drugs as e.g. antithrombotic agents, immunosuppressants is urgently needed. Therefore, it is crucial to advance our understanding of the fundamental factors involved in drug absorption, spanning from drug design to pathophysiology. With the growing knowledge in drug design and gastrointestinal pathophysiology, we anticipate the development of computer models that can accurately predict optimal absorption in the future.

Automated summary

This article focuses on the absorption of various drugs in patients with short bowel syndrome, including the characteristics of the drugs and the pharmacokinetic findings. Understanding the patient's gastrointestinal anatomy, the absorptive capacity of the remaining bowel, and the physicochemical properties of the drugs is crucial for optimizing oral pharmacotherapy.